Testing immunotherapy with chemotherapy or radiation for older adults with esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy or radiation for older adults with advanced or recurrent esophageal cancer. The goal is to see if this combination is safe and effective in treating the cancer and possibly slowing its growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 70 years old or older
- Have a confirmed diagnosis of squamous cell carcinoma of the esophagus (a common type of esophageal cancer). The cancer must be advanced, come back after surgery, or have spread to other parts of the body, and cannot be removed with surgery
- Have not received any prior cancer treatment for this esophageal cancer (including chemotherapy, radiation, or immunotherapy)
- Be in relatively good general health (able to care for yourself and be up and about more than half of your waking hours)
- Have at least one measurable tumor on imaging scans
- Have adequate organ function (blood counts, liver and kidney tests) and no active serious infections or autoimmune diseases
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy and radiation for older adults (70+) with advanced esophageal cancer that hasn't been treated before. The goal is to see if this approach can help control the cancer while keeping quality of life.
This trial tests whether giving chemotherapy after surgery, based on a blood test that finds tiny bits of cancer DNA, can improve outcomes for people with esophageal squamous cell carcinoma. The blood test helps decide who might benefit from extra treatment.
This study tests a new immunotherapy drug (tislelizumab) combined with chemotherapy before either surgery or radiation for esophageal cancer. The goal is to see if this combination helps shrink the tumor and improves outcomes, and it may offer a promising option for patients who meet the criteria.
This trial tests a drug called tislelizumab (an immunotherapy) in older adults (70+) with advanced esophageal cancer who cannot have standard chemotherapy. The goal is to see if the drug can slow or shrink the cancer safely.
This Phase 2 study tests whether adding tislelizumab (an immunotherapy drug) to chemotherapy before a combined course of chemotherapy and radiation can better treat locally advanced, non-surgable esophageal squamous cell cancer. It’s for adults who cannot have surgery and may help shrink the cancer and improve control of the disease.
This trial tests a combination of chemotherapy, immunotherapy, and a type of radiation that avoids nearby lymph nodes, given before surgery for a specific stage of esophageal cancer. The goal is to see if this approach can improve outcomes and make surgery more effective.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.